Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS

被引：25
|
作者：
Rice, GPA
Ebers, GC
Lublin, FD
Knobler, RL
机构：
[1] London Hlth Sci Ctr, London, ON N6A 5A5, Canada
[2] Med Coll Penn & Hahnemann Univ, Philadelphia, PA USA
[3] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
来源：
NEUROLOGY | 1999年 / 52卷 / 09期
关键词：
D O I：
10.1212/WNL.52.9.1893
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Flu-like symptoms and injection site reactions are adverse effects of treatment with interferon beta-1b in patients with MS. We compared gradual dose escalation, ibuprofen treatment, or their combination in an open-label study. The combination reduced the incidence of flu-like symptoms to rates comparable with the placebo group in the pivotal trial but increased the frequency of injection site reactions, albeit modestly and transiently.
引用
收藏
页码：1893 / 1895
页数：3
相关论文
共 50 条
  • [41] Gene expression profiling from blood samples of MS patients receiving interferon-beta 1b therapy
    Serrano-Fernández, P
    Koeczan, D
    Goertsches, R
    Möller, S
    Thiesen, HJ
    Zettl, UK
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S219 - S220
  • [42] Comparison of interferon β-1a subcutaneous and interferon β-1b on medication adherence in patients with multiple sclerosis
    Joyeux, A.
    Meletiche, D.
    Kozma, C.
    Dickson, M.
    Bennett, R.
    JOURNAL OF NEUROLOGY, 2009, 256 : S162 - S163
  • [43] Immunomodulatory effects of interferon-β-1b in patients with multiple sclerosis
    Ossege, LM
    Sindern, E
    Patzold, T
    Malin, JP
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (06) : 1085 - 1100
  • [44] Early versus delayed interferon beta-1b treatment in patients with a first event suggestive of MS:: the impact on progression of disability
    Kappos, L.
    Freedman, M. S.
    Polman, C. H.
    Edan, G.
    Hartung, H-P
    Miller, D.
    Montalban, X.
    Barkhof, F.
    Radue, E-W.
    Bauer, L.
    Lanius, V.
    Dahms, S.
    Pohl, C.
    Sandbrink, R.
    MULTIPLE SCLEROSIS, 2007, 13 : S50 - S51
  • [45] Session 1B - Plant biotechnology and genomics - Introduction to Session 1B
    Sticklen, Mariam B.
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2007, 137 : 205 - 205
  • [46] HEALTH ECONOMIC EVALUATION OF INTERFERON BETA 1B VERSUS 1A FOR PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
    Greene, M.
    Greene, N.
    VALUE IN HEALTH, 2016, 19 (03) : A69 - A70
  • [47] Successful Treatment under Interferon β-1b versus Progression after Discontinuation of Therapy in the Course of Disease of Two Sisters
    Korda, W.
    AKTUELLE NEUROLOGIE, 2012, 39 : S24 - S25
  • [48] Characterization of T cell responses to Interferon beta-1a/1b in NAB+ and NAB- MS patients and controls
    Kalluri, S. R.
    Hracsko, Z.
    Grummel, V.
    Biberacher, V.
    Pernpeintner, V.
    Buck, D.
    Hemmer, B.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 791 - 791
  • [49] The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS
    Inglese, M
    van Waesberghe, JHTM
    Rovaris, M
    Beckmann, K
    Barkhof, F
    Hahn, D
    Kappos, L
    Miller, DH
    Polman, C
    Pozzilli, C
    Thompson, AJ
    Yousry, TA
    Wagner, K
    Comi, G
    Filippi, M
    NEUROLOGY, 2003, 60 (05) : 853 - 860
  • [50] Treatment with peginterferon versus interferon in Chinese patients with hepatitis B
    Yu, Hai-bo
    Liu, En-qi
    Lu, She-min
    Zhao, Si-hai
    BIOMEDICINE & PHARMACOTHERAPY, 2010, 64 (08) : 559 - 564
12345